Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097-6110.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2024-11-15 DOI:10.3390/curroncol31110529

Alberto Alvarado-Miranda, Fernando Ulises Lara-Medina, Wendy R Muñoz-Montaño, Juan W Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesús Alberto Limón Rodríguez, Claudia Haydee Arce Salinas, Alberto Guijosa, Oscar Arrieta

引用次数: 0

Abstract

In the original publication [...].

查看原文本刊更多论文

更正：Alvarado-Miranda 等：《卡培他滨加芳香化酶抑制剂作为激素受体阳性、HER2 阴性转移性乳腺癌的一线疗法》。Curr.Oncol.2023, 30, 6097-6110.

在最初的出版物中 [......] 。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.